



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

18th November, 2021

Corporate Relationship Department
M/s. BSE Ltd.
Dalal Sreet, Fort
Mumbai 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclose herewith the disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 for your information.

Thanking you

Yours faithfully
For NATCO Pharma Limited

M. Adinarayana
Company Secretary &
Vice President (Legal and Corp Affairs)

Encl : as above



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/17/2021-2022

NATCO launches Tipanat tablets in India, for the treatment of advanced colorectal and gastric cancer

Hyderabad, India, November 18th, 2021

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has launched a novel fixed-dose combination of Trifluridine + Tipiracil for the first-time in India under the brand name **Tipanat** as a pack of 20 tablets in a bottle. **Tipanat** is a novel antineoplastic nucleoside analog indicated for the treatment of advanced colorectal and gastric cancer.

In India, approximately 1,25,000 new cases of the above-mentioned cancers are reported every year. **Tipanat** is of high importance in not only extending the survival but also in preserving the quality of life in the late lines of treatment which is currently an unmet medical need. NATCO has offered **Tipanat** at an affordable price.

Forwarded for favour of publication
For NATCO Pharma Limited

M Adinarayana
Company Secretary &
Vice president (Legal & Corp Affairs)

Ref: PR/ 15 /2021-22

Press Release

**NATCO Announces Launch of its 10mg strength for Everolimus Tablets
(generic for Afinitor®) in the US market**

NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816: Announces today that its marketing partner Breckenridge Pharmaceutical, Inc., US has launched the 10mg strength of Everolimus Tablets (generic for Afinitor®) in the US market. The U.S. Food and Drug Administration previously granted final approval of this Abbreviated New Drug Application. According to industry sales data, the 10mg strength of Afinitor generated annual sales of \$392 million during the twelve months ending July 2021. Breckenridge previously launched Everolimus tablets in 2.5mg, 5mg and 7.5mg strengths during the first quarter of 2021 in the US market.

**All brand names and trademarks are the property of their respective owners.*

Forwarded for favor of publication

For NATCO Pharma Limited

M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)